CN111559962A - 一种具有抗氧化活性的新酚酸类化合物的制备方法及应用 - Google Patents
一种具有抗氧化活性的新酚酸类化合物的制备方法及应用 Download PDFInfo
- Publication number
- CN111559962A CN111559962A CN202010672741.XA CN202010672741A CN111559962A CN 111559962 A CN111559962 A CN 111559962A CN 202010672741 A CN202010672741 A CN 202010672741A CN 111559962 A CN111559962 A CN 111559962A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- antioxidant activity
- chromatography
- acid compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 23
- -1 phenolic acid compound Chemical class 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- 238000010828 elution Methods 0.000 claims description 15
- 238000002953 preparative HPLC Methods 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 150000002989 phenols Chemical class 0.000 claims description 9
- 238000004440 column chromatography Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 5
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000004237 preparative chromatography Methods 0.000 claims description 4
- 239000001373 (E)-2-methylpent-2-enoic acid Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims description 2
- 241000628997 Flos Species 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims 5
- 239000002960 lipid emulsion Substances 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 abstract description 19
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 13
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract description 9
- 108010012715 Superoxide dismutase Proteins 0.000 abstract description 9
- 238000000338 in vitro Methods 0.000 abstract description 4
- 230000003834 intracellular effect Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 27
- 238000002835 absorbance Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 230000004792 oxidative damage Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000287 crude extract Substances 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 4
- 150000001336 alkenes Chemical group 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000736032 Sabia <angiosperm> Species 0.000 description 1
- 241000081623 Sabia parviflora Species 0.000 description 1
- 241001083952 Sabiaceae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical group O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
- C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010672741.XA CN111559962B (zh) | 2020-07-14 | 2020-07-14 | 一种具有抗氧化活性的新酚酸类化合物的制备方法及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010672741.XA CN111559962B (zh) | 2020-07-14 | 2020-07-14 | 一种具有抗氧化活性的新酚酸类化合物的制备方法及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111559962A true CN111559962A (zh) | 2020-08-21 |
| CN111559962B CN111559962B (zh) | 2020-10-30 |
Family
ID=72068894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010672741.XA Active CN111559962B (zh) | 2020-07-14 | 2020-07-14 | 一种具有抗氧化活性的新酚酸类化合物的制备方法及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111559962B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040162272A1 (en) * | 2003-02-19 | 2004-08-19 | L'oreal S.A. | Chemical enhancer and method |
| WO2006014674A2 (en) * | 2004-07-23 | 2006-02-09 | Polnox Corporation | Anti-oxidant macromonomers and polymers and methods of making and using the same |
| US20090035245A1 (en) * | 2005-04-19 | 2009-02-05 | L'oreal | Deodorant cosmetic composition comprising a combination of a lipophilic salicylic acid derivative and an antiperspirant aluminium salt |
| CN107501250A (zh) * | 2017-08-23 | 2017-12-22 | 江西本草天工科技有限责任公司 | 苯并呋喃酮类衍生物及其制备方法和用途 |
| CN111253247A (zh) * | 2020-04-27 | 2020-06-09 | 江西本草天工科技有限责任公司 | 一种具有抗炎活性的新酚酸类化合物的制备方法及应用 |
-
2020
- 2020-07-14 CN CN202010672741.XA patent/CN111559962B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040162272A1 (en) * | 2003-02-19 | 2004-08-19 | L'oreal S.A. | Chemical enhancer and method |
| WO2006014674A2 (en) * | 2004-07-23 | 2006-02-09 | Polnox Corporation | Anti-oxidant macromonomers and polymers and methods of making and using the same |
| US20090035245A1 (en) * | 2005-04-19 | 2009-02-05 | L'oreal | Deodorant cosmetic composition comprising a combination of a lipophilic salicylic acid derivative and an antiperspirant aluminium salt |
| CN107501250A (zh) * | 2017-08-23 | 2017-12-22 | 江西本草天工科技有限责任公司 | 苯并呋喃酮类衍生物及其制备方法和用途 |
| CN111253247A (zh) * | 2020-04-27 | 2020-06-09 | 江西本草天工科技有限责任公司 | 一种具有抗炎活性的新酚酸类化合物的制备方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111559962B (zh) | 2020-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111410643B (zh) | 一种新的肉桂酰酯儿茶素及四种新的苯丙素黄烷生物碱制备和应用 | |
| CN111961022B (zh) | 一种具有神经保护作用的双黄酮类化合物及其提取分离方法 | |
| CN102516344B (zh) | 一种具有抗肿瘤活性的化合物及其制备方法和应用 | |
| CN102127042B (zh) | 一类高异黄酮化合物及制备方法和用途 | |
| CN115521245B (zh) | 马齿苋中一种生物碱类化合物及其提取分离方法与应用 | |
| CN103739652B (zh) | 一种23,29-降齐墩果烷酸化合物及其制备方法和在制备糖苷酶抑制剂药物中的用途 | |
| CN113968862B (zh) | 马齿苋中两种新生物碱及其提取分离方法 | |
| CN111253247B (zh) | 一种具有抗炎活性的新酚酸类化合物的制备方法及应用 | |
| CN111848565B (zh) | 单萜基双香豆素类化合物、药物组合物及其制备方法和用途 | |
| CN111559962B (zh) | 一种具有抗氧化活性的新酚酸类化合物的制备方法及应用 | |
| CN103739653B (zh) | 一种23-降齐墩果烷酸化合物及其制备方法和在制备糖苷酶抑制剂药物中的用途 | |
| CN114989064B (zh) | 马齿苋中一种新型吡咯生物碱类化合物及其提取分离方法 | |
| CN103613632B (zh) | 29-降齐墩果烷酸类化合物及其制备方法和在制备糖苷酶抑制剂药物中的应用 | |
| CN103641882B (zh) | 新的2,3二羟基-30-降齐墩果酸及其制备方法和在制备糖苷酶抑制剂药物中的应用 | |
| CN113754620B (zh) | 火麻仁中的木脂素酰胺类化合物及其制备方法和应用 | |
| CN114369076B (zh) | 马齿苋中两种茚类化合物及其提取分离方法 | |
| CN103204860B (zh) | 具有神经保护作用的石蒜科生物碱类化合物 | |
| CN103638031B (zh) | 化合物quinatic acid的制备方法和在制备糖苷酶抑制剂药物中的应用 | |
| CN116283510B (zh) | 马齿苋中一种新型苯酚类化合物及其提取分离方法 | |
| CN113336627B (zh) | 单萜类化合物及其制备方法和用途 | |
| CN103193788B (zh) | 一个具有神经保护作用的石蒜碱类化合物 | |
| CN102675105A (zh) | 一种烟草中的酚类化合物及其制备方法和应用 | |
| CN108440249A (zh) | 一种制备天然天麻苷元的方法 | |
| CN107188879B (zh) | 一种双苯骈型香豆素类化合物及其制备方法和应用 | |
| CN103382194A (zh) | 一种二萘醌化合物、其衍生物及其盐的制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220129 Address after: 330000 Xingwan Avenue 818, Wanli District, Nanchang City, Jiangxi Province Patentee after: JIANGXI University OF TRADITIONAL CHINESE MEDICINE Patentee after: JIANGXI HERBFINE HI-TECH Co.,Ltd. Patentee after: JIANGXI BENCAO TIANGONG BIOTECHNOLOGY CO.,LTD. Address before: 330000 Xingwan Avenue 818, Wanli District, Nanchang City, Jiangxi Province Patentee before: JIANGXI University OF TRADITIONAL CHINESE MEDICINE Patentee before: Jiangxi Bencao Tiangong Technology Co., Ltd |
|
| TR01 | Transfer of patent right |